EUR 132.8
(5.23%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | -2.02 Million EUR | -11.52% |
2022 | -1.81 Million EUR | -21.57% |
2021 | -1.49 Million EUR | 0.0% |
2020 | - EUR | -100.0% |
2019 | 4000.00 EUR | 0.0% |
2018 | - EUR | 0.0% |
2017 | - EUR | -100.0% |
2016 | 302 Thousand EUR | 30100.0% |
2015 | 1000.00 EUR | 0.0% |
2014 | - EUR | 0.0% |
2013 | - EUR | 0.0% |
2012 | - EUR | 0.0% |
2011 | - EUR | 0.0% |
2010 | - EUR | 0.0% |
2009 | - EUR | 0.0% |
2008 | - EUR | 0.0% |
2007 | - EUR | 0.0% |
2006 | - EUR | 0.0% |
2005 | - EUR | -100.0% |
2004 | 2000.00 EUR | 0.0% |
2003 | - EUR | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q2 | -858.02 Thousand EUR | 0.0% |
2023 Q4 | 900.65 Thousand EUR | 0.0% |
2023 Q2 | 107.86 Thousand EUR | 0.0% |
2023 FY | -2.02 Million EUR | -11.52% |
2022 FY | -1.81 Million EUR | -21.57% |
2022 Q2 | - EUR | 0.0% |
2022 Q4 | -1.11 Million EUR | 0.0% |
2021 Q2 | - EUR | 0.0% |
2021 FY | -1.49 Million EUR | 0.0% |
2021 Q4 | -1.49 Million EUR | 0.0% |
2020 Q4 | - EUR | 0.0% |
2020 FY | - EUR | -100.0% |
2020 Q2 | - EUR | 0.0% |
2019 FY | 4000.00 EUR | 0.0% |
2019 Q2 | - EUR | 0.0% |
2019 Q4 | 552 Thousand EUR | 0.0% |
2018 FY | - EUR | 0.0% |
2018 Q1 | - EUR | 0.0% |
2018 Q4 | 750.00 EUR | 0.0% |
2018 Q2 | - EUR | 0.0% |
2017 Q2 | - EUR | 0.0% |
2017 FY | - EUR | -100.0% |
2017 Q4 | - EUR | 0.0% |
2017 Q1 | - EUR | 0.0% |
2016 FY | 302 Thousand EUR | 30100.0% |
2016 Q4 | - EUR | 0.0% |
2016 Q2 | - EUR | 0.0% |
2016 Q1 | - EUR | 0.0% |
2015 FY | 1000.00 EUR | 0.0% |
2015 Q3 | - EUR | 0.0% |
2015 Q4 | - EUR | 0.0% |
2015 Q2 | - EUR | 0.0% |
2015 Q1 | - EUR | 0.0% |
2014 Q4 | - EUR | 0.0% |
2014 FY | - EUR | 0.0% |
2014 Q3 | - EUR | 0.0% |
2014 Q1 | - EUR | 0.0% |
2014 Q2 | - EUR | 0.0% |
2013 Q2 | - EUR | 0.0% |
2013 Q1 | - EUR | 0.0% |
2013 Q4 | - EUR | 0.0% |
2013 Q3 | - EUR | 0.0% |
2013 FY | - EUR | 0.0% |
2012 Q1 | - EUR | 0.0% |
2012 FY | - EUR | 0.0% |
2012 Q3 | - EUR | 0.0% |
2012 Q4 | - EUR | 0.0% |
2012 Q2 | - EUR | 0.0% |
2011 Q3 | - EUR | 0.0% |
2011 FY | - EUR | 0.0% |
2011 Q4 | - EUR | 0.0% |
2011 Q2 | - EUR | 0.0% |
2011 Q1 | - EUR | 0.0% |
2010 Q4 | - EUR | 0.0% |
2010 Q1 | - EUR | 0.0% |
2010 FY | - EUR | 0.0% |
2010 Q3 | - EUR | 0.0% |
2010 Q2 | - EUR | 0.0% |
2009 Q4 | - EUR | 0.0% |
2009 Q1 | - EUR | 0.0% |
2009 Q2 | - EUR | 0.0% |
2009 FY | - EUR | 0.0% |
2009 Q3 | - EUR | 0.0% |
2008 Q1 | - EUR | 0.0% |
2008 Q3 | - EUR | 0.0% |
2008 Q2 | - EUR | 0.0% |
2008 Q4 | - EUR | 0.0% |
2008 FY | - EUR | 0.0% |
2007 Q2 | - EUR | 0.0% |
2007 Q4 | - EUR | 0.0% |
2007 Q1 | - EUR | 0.0% |
2007 Q3 | - EUR | 0.0% |
2007 FY | - EUR | 0.0% |
2006 Q1 | - EUR | 0.0% |
2006 Q2 | - EUR | 0.0% |
2006 Q3 | - EUR | 0.0% |
2006 Q4 | - EUR | 0.0% |
2006 FY | - EUR | 0.0% |
2005 FY | - EUR | -100.0% |
2005 Q4 | - EUR | 0.0% |
2005 Q3 | - EUR | 0.0% |
2005 Q2 | - EUR | 0.0% |
2005 Q1 | - EUR | 0.0% |
2004 Q4 | - EUR | -100.0% |
2004 Q2 | 500.00 EUR | 0.0% |
2004 Q3 | 500.00 EUR | 0.0% |
2004 Q1 | 500.00 EUR | 0.0% |
2004 FY | 2000.00 EUR | 0.0% |
2003 Q3 | - EUR | 0.0% |
2003 FY | - EUR | 0.0% |
2003 Q2 | - EUR | 0.0% |
2003 Q1 | - EUR | 0.0% |
2003 Q4 | 500.00 EUR | 0.0% |
2002 Q4 | - EUR | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
Nicox S.A. | -11.5 Million EUR | 82.356% |
European Medical Solutions | 13.51 Million EUR | 115.022% |
FERMENTALG | 535 Thousand EUR | 479.362% |
argenx SE | 925.49 Million EUR | 100.219% |
BioSenic S.A. | 543 Thousand EUR | 473.773% |
Celyad Oncology SA | 33 Thousand EUR | 6250.258% |
Hyloris Pharmaceuticals SA | 1.99 Million EUR | 201.785% |
Onward Medical N.V. | -14.81 Million EUR | 86.303% |
Oxurion NV | 104 Thousand EUR | 2051.524% |
PHAXIAM Therapeutics S.A. | 1.32 Million EUR | 253.061% |
UCB SA | 3.34 Billion EUR | 100.061% |